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Abstract
Background: Studies intending to measure drug-induced changes in learning and memory are challenged to
parse out the effects of drugs on sensory, motor, and associative systems in the brain. In the context of
conditioned taste aversion (CTA), drugs that alter the sensorium of subjects and affect their ability to taste and/or
feel malaise may limit the ability of investigators to make conclusions about associative effects of these substances.
Since the GABAergic system is implicated in inhibition, the authors were hopeful to use the GABA agonist,
baclofen (BAC), to enhance extinction of a CTA, but first a preliminary evaluation of BAC’s peripheral effects on
animals’ sensorium had to be completed due to a lack of published literature in this area.
Findings: Our first experiment aimed to evaluate the extent to which the GABAB agonist, BAC, altered the ability
of rats to differentiate between 0.3% and 0.6% saccharin (SAC) in a two bottle preference test. Here we report that
2 or 3 mg/kg (i.p.) BAC, but not 1 mg/kg BAC, impaired animals’ gustatory discrimination abilities in this task.
Furthermore, when SAC consumption was preceded by 2 or 3 mg/kg (i.p.) BAC, rats depressed their subsequent
SAC drinking.
A second experiment evaluated if the suppression of SAC and water drinking (revealed in Experiment 1) was
mediated by amnesiac effects of BAC or whether BAC possessed US properties in the context of the CTA
paradigm. The time necessary to reach an asymptotic level of CTA extinction was not significantly different in
those animals that received the 3 mg/kg dose of BAC compared to more conventionally SAC + lithium chloride
(LiCl, 81 mg/kg) conditioned animals.
Conclusions: Our findings were not consistent with a simple amnesia-of-neophobia explanation. Instead, results
indicated that 2 and 3 mg/kg (i.p.) BAC were capable of inducing a CTA, which was extinguishable via repeated
presentations of SAC only. Our data indicate that, depending on the dose, BAC can alter SAC taste discrimination
and act as a potent US in the context of a CTA paradigm.
Background
GABAergic (g-Aminobutyric acid) systems play an impor-
tant role in learning, memory, and inhibitory processes
[1-3]. Baclofen [BAC; (±)-b-(Aminomethyl)-4- chloroben-
zenepropanoic acid.] is a GABAB receptor agonist that has
been used extensively in studies aimed at determining the
role of GABA receptors in learning and memory. Baclofen
causes passive avoidance deficits [4], spatial memory
impairments [1,5,6] impairments in memory retention [3]
and other disturbances of memory either through the
disruption of acquisition and/or consolidation of learned
responses [3,4,6,7]. Additionally, GABAB antagonists have
been shown to attenuate both BAC-induced and scopola-
mine-induced spatial working and reference memory defi-
cits in the Morris water maze [8].
A variety of behavioral and physiological side effects
linked to GABAergic system manipulations have
obscured our understanding of the role this system may
play in memory formation and retention. For example,
hypodipsia, sedation, vertigo [9], and hyperphagia [10]
have followed BAC administration. Rats injected intra-
peritoneally with BAC displayed both hyperdipsic and
hyperphagic responses [10,11]. These behaviors were
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any medium, provided the original work is properly cited.reversed, in rats, using systemic and intracerebroventri-
cular injections of the GABAB antagonist, CGP35348
[11]. Infusions of BAC in the median raphe nuclei also
led to increased eating behaviors, but did not affect
drinking behaviors [12].
Other laboratories failed to find BAC-induced changes
in appetitive behaviors. For example, Chester and Cun-
ningham [13] showed that BAC does not alter ethanol-
induced conditioned taste aversion in mice, nor does
BAC, itself, have malaise inducing properties at a dose
of 2 mg/kg. Experiments by Jacobson and colleagues
[4,14] used genetically altered mice lacking specific sub-
types of the GABAB receptor and reported a vital role
for the GABAB system in conditioned emotional
responses and conditioned taste aversion (CTA) acquisi-
tion/extinction. For example, it was demonstrated that
GABAB(1a) knockout mice fail to acquire a CTA while
GABAB(1b) knockouts failed to extinguish a CTA [14].
Given the role of the GABAB system in mediating
learning and memory and its specific involvement in
CTA learning and consummatory behaviors, combined
with the increasing frequency of BAC use in learning,
memory and addiction research, we were drawn to
investigate the effects of BAC on acquisition and extinc-
tion using the CTA paradigm in rats. The aforemen-
tioned side-effects of BAC have not been extensively
investigated in the context of how they may adversely
influence the interpretation of taste-dependant learning
paradigms, specifically the CTA paradigm. A CTA may
be acquired when an animal consumes a novel taste
(conditioned stimulus; CS) and then experiences symp-
toms of poisoning (unconditioned stimulus; US). When
later given a choice between the poisoned taste and
water, the animal will avoid the taste previously asso-
ciated with malaise [15]. However, when designing ani-
mal experiments that utilize the CTA methodology
along with systemic administration of neuro-active
drugs, there are several considerations to which an
investigator must attend: (a) does the drug alter basal
food or liquid consumption? (b) does the drug compro-
mise the animals’ ability to perceive the conditioned sti-
mulus (CS)? (c) does the drug cause malaise itself, thus
acting as an US or interfering with actions of an US?
Without this information, investigators may draw erro-
neous conclusions, attributing a drug-induced disruption
in performance to a drug-induced learning deficit rather
than a drug-induced alteration in sensory capabilities
and concurrent task performance. Due to the disparity
of findings regarding BAC and other GABAB system
agonists’ effects on consummatory behaviors
[4,10,11,14], the present experiments attempted to
establish the feasibility of using BAC in behavioral stu-
dies that employ taste paradigms, specifically CTA. Spe-
cifically, the aims of the present studies were to (a)
determine whether or not BAC, at doses of 1, 2, or 3
mg/kg (i.p.) altered the perceived gustatory discrimina-
tion capability of animals in a two bottle preference test
of SAC (0.3% SAC versus 0.6% SAC), and (b) to deter-
mine, via a CTA paradigm, if the observed deficiencies
in gustatory discrimination capabilities may have been
due to possible US effects of the BAC injection.
Findings
Methods: experiment 1
Animals
Ten naïve male and 10 naïve female Sprague-Dawley
rats (Mean weight ± SEM = 440.15 ± 29.04 g; Mean age
± SEM = 129 ± 18 days), derived from the Harlan
strain, were supplied by the Baldwin-Wallace College
breeding colony (Berea, Ohio). Due to budget con-
straints the laboratory was only able to gain access to a
certain number of rats from the institution’s own breed-
ing colony. The sex differences were of initial concern,
but precautions were taken that included counterbalan-
c i n gm a l e sa n df e m a l e sw i t h i ng r o u p sa sw e l la se n s u r -
ing animals’ ages were consistent and animals’ body
weights were not statistically different between and
within groups. Furthermore, analyses were run to check
for differences in fluid consumption (SAC and water) on
each day between sexes in each treatment group. Proce-
d u r e sw e r ea p p r o v e db yt h eB a l d w i n - W a l l a c eC o l l e g e
Institutional Animal Care and Use Committee. Animals
were procured and cared for according to the recom-
mendations in the Guide for the Care and Use of
Laboratory Animals [16] and in compliance with the
Animal Welfare Act.
Throughout the experiment, the animals were housed
in plastic ‘shoe box’ cages (20 cm × 22 cm × 20 cm
deep) in a temperature-controlled room under a 12-hr
light/dark cycle (lights on at 06:00 hrs). Rats had free
access to food (Purina Rodent Chow, No. 5001, PMI
Nutrition International, Brentwood, MO) but underwent
fluid deprivation as described below. Throughout the
study, the daily bottle weight differentials were recorded
to the nearest 0.1 g (1 g of liquid = 1 ml of liquid).
Drug treatments and groups
Rats were randomly assigned to one of four drug-treat-
ment groups (see Table 1). The groups received either 1
mg/kg (i.p.) of BAC (BAC 1 mg/kg; N = 5), 2 mg/kg (i.
p.) of BAC (BAC 2 mg/kg; N = 5), or 3 mg/kg (i.p.) of
BAC (BAC 3 mg/kg; N = 5). Male and female rats were
randomly assigned to drug treatment groups. This
resulted in 2 males and 3 females or vice versa in each
group. All BAC injections were administered at a
volume of 1 ml/kg. A fourth group of animals received
sterile physiological saline (0.9% sodium chloride; 1 ml/
kg, i.p.) (SAL; N = 5). All chemicals were purchased
from Sigma Aldrich (St. Louis, MO) and drugs were
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injections. The baclofen used in this study was a race-
mic mixture: (±)-b-(Aminomethyl)-4- chlorobenzene-
propanoic acid.
Procedures
Two days prior to the first tastant discrimination test, all
animals were introduced to a 23-hr fluid deprivation
cycle. The fluid deprivation cycle consisted of a 1 hr
presentation of fluid/day to ensure animals were moti-
vated to drink at the time liquid was present. On the
first day of fluid deprivation, animals were given 1 hr of
water only. The 1 hr fluid pres e n t a t i o no c c u r r e da tt h e
same time of day throughout the study (12:00-13:00
hrs).
O nD a y1o ft h es t u d y ,r a t sw e r es i m u l t a n e o u s l y
offered 0.3% and 0.6% SAC solutions (2 bottle test) for
30 min (this is referred to in Table 1 as “First Taste
Exposure”). The First Taste Exposure day was an
attempt to reduce the effects of neophobia during the
subsequent days when we used SAC consumption to
assess BAC’s ability to act as a US and its effects on
taste discrimination. While rats will sample from both
concentrations, they will reliably show a preference for
0.3% SAC over 0.6% SAC [refer to [17]]. However,
water-deprived rats also tend to drink voraciously from
the first source of liquid they encounter. Therefore in
this study, the positions of our 2 bottles/cage were
switched at 1, 5 and 10 min into the first 30-min pre-
sentation of liquid each day. Immediately following the
2-bottle SAC presentations the animals were given
water for 30 min to prevent dehydration.
Discrimination testing took place on Days 2 and 4 of
the study during which animals were given an injection
o fB A Co rS A L3 0m i np r i o rt oa n yS A Ce x p o s u r e .
BAC’s half-life is approximately 4 hrs following i.p.
administration of the drug in rats and it has been
shown to become pharmacologically active within 15
min, [2,18]. Thirty min following the injections animals
were simultaneously presented with two different bottles
of SAC (0.3% and 0.6%, %w/v) for a 30 min period, and
bottle switching occurred as described for CS presenta-
tion on Day 1, the First Taste Exposure Day.
Animals were given one rest day (Day 3) following the
first discrimination test during which they were allowed
1 hr access of water only and were given no drug injec-
tion. This rest day was designed to allow rehydration
and time for the metabolism of the drugs given the day
before. Animals were given two bottles of water during
the first 30 min so that bottle positions could be
switched as described above.
Statistical analysis
A Repeated Measures Analysis of Variance (RM-
ANOVA) test was used to evaluate the differences in
volumes of 0.3% and 0.6% SAC consumed by rats in
each of the drug treatment groups on the discrimination
test days as well as the first taste exposure day [SAC
Concentration (0.3% or 0.6%) × Drug Treatment (SAL,
1, 2, 3 mg/kg BAC) × Test Days (first taste exposure,
discrimination test 1 and test 2)]. We also ran one-way
ANOVAs and Tukey post hocs to determine differences
between drug-treatment groups for the following mea-
sures: the total SAC consumption (0.3% SAC + 0.6%
SAC) per day, total fluid consumption (SAC + H20; on
BAC-injection days 2 and 4) per day, and water con-
sumption on Day 3 (when there were no injections and
only water was offered). A one-way ANOVA and Tukey
post hoc tests were run to determine if there was a sig-
nificant difference in total fluid consumption or H2O
consumption among treatment groups [Drug treatment:
SAL, 1, 2, 3 mg/kg BAC]. The RM-ANOVA and one-
way ANOVA with Tukey post hoc tests previously
noted were repeated using ‘milliliters per 100 g of body
weight’ (ml consumed/100 g) instead of the direct milli-
liter consumption measure in order to ensure there
were no variances in reported observations that could
be attributable to body weight differences. Furthermore,
a one-way ANOVA was also run to determine if body
weights were significantly different within or between
groups. Finally, a t-test was run to compare daily fluid
consumption (SAC and water) of males versus females
in each group.
All statistical analyses were run using the Statistical
Package for Social Sciences software (SPSS) (Chicago,
IL) and a was set at 0.05 for all tests.
Table 1 Experiment 1 - Group nomenclature and treatments
Group Nomenclature N First Taste Exposure Discrimination Tests Days 1 and 3 Rest Days Days 2 and 4
SAL 5 SAC
a SAL
b + SAC
a Water
BAC 1 mg/kg 5 SAC BAC
c + SAC Water
BAC 2 mg/kg 5 SAC BAC + SAC Water
BAC 3 mg/kg 5 SAC BAC + SAC Water
aSAC = two-bottle SAC preference test using 0.3%SAC and 0.6%SAC [%w/v; SAC salt dissolved in deionized water to specific concentration]
bSAL = physiological saline injection (0.9% NaCl dissolved in deionized water; 1 ml/kg, i.p.)
cBAC = BAC injection (BAC dissolved in physiological saline to either 1, 2 or 3 mg/ml; 1 ml/kg, i.p.; dosing specified in group nomenclature)
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On the first taste exposure day, when no drug injections
were given, all groups showed a preference for 0.3%
SAC despite the overall low SAC consumption due to
neophobia [Mean SAC consumptions ± SEM: 0.3% SAC
= 5.2 ± 1.1 ml; 0.6% SAC = 2.3 ± 0.7 ml]. Further, the
SAL and BAC 1 mg/kg groups showed a statistically sig-
nificant preference for 0.3% SAC over 0.6% SAC on
both discrimination test days (when drug injections
were administered prior to SAC presentation), indicating
that their taste discrimination was intact. Saline-treated
rats drank significantly more 0.3% SAC than 0.6% SAC
during both discrimination tests as shown by RM-ANO-
VAs [Test 1: F(1, 3) = 10.260, p = 0.049; Test 2: F(1, 4)
= 18.978, p =0 . 0 2 2 ] .T h eBAC 1 mg/kg group also
drank significantly more 0.3% SAC than 0.6% SAC on
both test days [Test 1: F(1, 4) = 11.014, p = 0.029; Test
2: F(1, 4) = 49.239, p =0 0 2 ] .H o w e v e r ,t h eBAC 2 mg/
kg and BAC 3 mg/kg groups drank statistically similar
volumes of each SAC concentration on both test days,
demonstrating a disruption in taste discrimination. Refer
to Figure 1 for graphical representation of the first taste
exposure day and the discrimination test days.
A significant drug treatment effect on total SAC con-
sumption (0.3% + 0.6% SAC) and total fluid consump-
tion (SAC + H2O) was observed on days when BAC
was administered [F(3, 16) = 9.148, p = 0.001]. Total
SAC consumption was significantly lower in the BAC 2
mg/kg and BAC 3 mg/kg groups compared to the SAL
and BAC 1 mg/kg groups. Mean total fluid consump-
tion on these BAC-injection days was significantly less
for BAC 3 mg/kg animals compared to SAL and BAC 1
mg/kg animals [F(3, 16) = 6.717, p = 0.004], an indica-
tion of dose-dependent hypodipsia. However, the mean
fluid consumption on BAC injection days did not differ
significantly between the BAC 2 mg/kg animals com-
pared to any of the other three groups. Total fluid con-
sumption (H2O only) on the rest day (Day 3), when
BAC was not administered, did not differ among any
drug-treatment groups.
A dose-dependent effect on overall SAC consumption
was demonstrated across the two discrimination test
days [F(3, 15) = 7.059, p = 0.004]. There was a signifi-
cant decrease in total SAC consumption from the first
discrimination test day to the second discrimination test
day in the BAC 2 mg/kg and BAC 3 mg/kg groups.
Moreover, total SAC consumed was significantly less in
these groups compared to the SAL and BAC 1 mg/kg
group, as illustrated by Tukey post hoc comparisons.
Additionally, the SAL and BAC 1 mg/kg groups showed
a significant increase in total SAC consumption from
the first taste exposure day to the second discrimination
test day; this effect was opposite the decrease in SAC
consumption observed in the rats receiving higher doses
of BAC.
There were no significant differences between SAC or
water consumption between males and females within
the same group, as illustrated by t-test comparisons, nor
was there a significant difference in average weight
among drug-treatment groups, as illustrated by a one-
way ANOVA comparison. Furthermore, the statistical
differences reported in fluid consumption remained
Figure 1 Experiment 1-Evaluation of 0.3% versus 0.6% SAC Discrimination. Mean ml SAC Consumption (± SEM) on the First Taste Exposure
Day and both SAC Discrimination Test Days. RM-ANOVA showed that on the First Taste Exposure, in the absence of any drug treatment or other
behavioral manipulation, all animals drank significantly more 0.3% SAC in comparison to 0.6% SAC. Also, RM-ANOVA showed that on both SAC
Discrimination Test Days the SAL and BAC 1 mg/kg groups drank significantly more 0.3% SAC than 0.6% SAC. The BAC 2 mg/kg and BAC 3 mg/
kg groups did not drink significantly different amounts of 0.3% SAC and 0.6% SAC on either test day. The SAL and BAC 1 mg/kg groups also
showed a steady increase in 0.3% SAC consumption between the First Taste Exposure and Test 2 (the final taste exposure), but the BAC 2 mg/
kg and BAC 3 mg/kg groups did not increase their consumption of 0.3% SAC. * Significant within group difference between 0.3% and 0.6% SAC.
p < 0.05
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weight’ w a su s e da st h ed e p e n d e n tv a r i a b l ei nt h eR M -
ANOVAs and one-way ANOVAs, indicating that weight
variances did not impact reported results.
Discussion: experiment 1
Our first experiment showed that, in a dose-dependent
manner, BAC appeared to disrupt drinking behavior in
rats and limited their ability to discriminate between 2
different SAC concentrations. But, due to the signifi-
cantly decreased SAC consumption from discrimination
t e s t1t ot e s t2o b s e r v e di nt h eBAC 2 mg/kg and BAC
3m g / k ggroups, it was still unclear as to what extent
BAC was only altering the ability of rats to discriminate
between the two different SAC concentrations and to
what extent BAC may have either been exerting putative
amnesiac effects or simultaneously acting as an US.
Thus, we wished to further investigate the two BAC
doses that induced disruptions in taste discrimination
tests (BAC 2 mg/kg and BAC 3 mg/kg groups).
In the following experiment animals were presented
with a novel taste (0.3% SAC) paired with BAC or LiCl.
Lithium chloride was chosen as a comparison measure
since it is a more conventional and well-established US
found in many other taste aversion studies [15,18-21]. If
animals steadily decreased their SAC consumption to
nearly zero over the three acquisition trials we could
conclude that BAC was acting as an US. On the other
hand, if animals continued to drink levels of SAC com-
parable to the first presentation of SAC (i.e. persistent
neophobia), we could conclude that animals were
experiencing anterograde amnesia due to BAC, an effect
typical of GABA agonist administration [1,22].
Methods: experiment 2
Animals
Twenty-nine naive male Sprague-Dawley rats (Mean
w e i g h t±S E M=4 6 7 . 7 4±3 8 . 4 3g ;M e a na g e±S E M=
117 ± 10 days), derived from the Harlan strain, were
supplied by the Baldwin-Wallace College breeding col-
ony (Berea, Ohio). Rats had free access to food but
underwent fluid deprivation as described below. Proce-
d u r e sw e r ea p p r o v e db yt h eB a l d w i n - W a l l a c eC o l l e g e
Institutional Animal Care and Use Committee. Animals
were procured and cared for according to the recom-
mendations in the Guide for the Care and Use of
Laboratory Animals [16] and in compliance with the
Animal Welfare Act.
Drug treatments
Animals received one of three main drug treatments
throughout the conditioning phase: LiCl (81 mg/kg; i.p.),
BAC (2 mg/kg; i.p.) or BAC (3 mg/kg; i.p.) These doses
of BAC were chosen based on the observations of
Experiment 1 showing that they not only caused a
disruption in SAC discrimination but also significantly
reduced SAC consumption compared to the SAL or 1
mg/kg BAC injection groups. The 81 mg/kg dose of
LiCl (i.p.) was chosen specifically based on our previous
work demonstrating that 3 pairings of SAC and LiCl (81
mg/kg, i.p.) create a strong aversion to SAC in adult
rats that is only extinguished upon multiple exposures
of SAC alone [refer to [21]]. All drug solutions were
made immediately prior to injections. Chemicals were
purchased from Sigma Aldrich (St. Louis, MO). The
baclofen used in this study was a racemic mixture:
(±)-b-(Aminomethyl)-4- chlorobenzenepropanoic acid.
Three groups (SAC + LiCl, SAC + BAC 2 mg/kg, and
SAC + BAC 3 mg/kg) received traditional taste aversion
training in which the CS tastant was immediately fol-
lowed by injection of the US (either 81 mg/kg LiCl, 2
mg/kg BAC, or 3 mg/kg BAC). In addition to the
groups receiving conventional CTA training, there were
three explicitly unpaired (EU) control groups [EU(LiCl),
EU(BAC 2 mg/kg) and EU(BAC 3 mg/kg)]t h a t
received the CS tastant and 24 h later received a 30 min
presentation of water followed immediately by an injec-
tion of either LiCl (81 mg/kg) or BAC (2 mg/kg or 3
mg/kg). The EU(LiCl) group revealed how normal, non-
conditioned animals drink SAC, while simultaneously
controlling for residual effects of LiCl and SAC exposure
through the explicitly unpaired, non-associative method.
Likewise, we controlled for the residual effects of BAC
(2 and 3 mg/kg) in non-conditioned animals using the
aforementioned EU(BAC 2 mg) and EU(BAC 3 mg)
groups that received three explicitly unpaired exposures
to BAC (2 or 3 mg/kg) and SAC. Refer to Table 2 for
group nomenclature and treatments.
CTA acquisition
Animals were introduced to a 23-hr fluid deprivation
schedule 2 days prior to the CTA conditioning phase of
the study. Two 30-min presentations of water were
Table 2 Experiment 2 - Group nomenclature and
treatments
Group Nomenclature N Conditioning Extinction
Days 1, 3, 5 Days 2, 4, 6
SAC + BAC 2 mg/kg 5 SAC
1 + BAC
2 Water SAC
SAC + BAC 3 mg/kg 4 SAC + BAC Water SAC
SAC + LiCl 5 SAC + LiCl
3 Water SAC
EU(BAC 3 mg) 5 SAC Water + BAC
EU(BAC 2 mg) 5 SAC Water + BAC
EU(LiCl) 5 SAC Water + LiCl
1SAC = 30 min presentation of 0.3% SAC [%w/v; SAC salt dissolved in
deionized water]
2BAC = BAC injection (BAC dissolved in physiological saline to either 2 or 3
mg/ml; 1 ml/kg, i.p.; dosing specified in group nomenclature)
3LiCl = LiCl injection (81 mg/ml LiCl dissolved in physiological saline; dose =
81 mg/kg, i.p)
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12:30 hrs and 12:45-13:15 hrs). This fluid deprivation
paradigm has been used in previously published studies
by our own laboratory [21]. Alternate and less severe
fluid deprivation methods, including a gradual reduction
in fluid presentation [23,24] were less appropriate for
our study since it was imperative that all animals were
similarly and highly motivated to drink upon the first
CS exposure. Since the animals were given an hour
access to fluid every day, the stress induced by this
deprivation schedule should have been minimal. There
is other literature supporting similar fluid deprivation
schedules in conditioned taste aversion paradigms,
which not only validate the procedure but also allow for
easier comparison of our methods and findings
[4,14,25-27].
The conditioning phase lasted a total of 6 days (see
Table 2). On days 1, 3 and 5 of the study, all groups of
animals were presented with SAC (0.3%;%w/v) for a 30
min period. Immediately following the drinking session
animals were injected (i.p.) with one of the two doses of
BAC or saline, depending on their group assignment.
The SAC + LiCl group was given an injection of LiCl (81
mg/kg, i.p.) at this time while the EU(LiCl), EU(BAC 2
mg),a n dEU(BAC 3 mg) controls received a physiologi-
cal saline injection (1 ml/kg, i.p.) following the presenta-
tion of SAC. Fifteen min after the injections, these 3
groups were given another 30-min presentation of water
to prevent dehydration. On the rest days (days 2, 4 and
6), the SAC + LiCl and SAC + BAC animals were not
given any drug injections and were presented with water
for two 30-min sessions, separated by 15 min.
The EU controls received both a CS (SAC) and US
(LiCl, BAC 2 mg/kg, or BAC 3 mg/kg depending on
designated group) presentation, but in an explicitly
unpaired (EU) temporal relationship that prevented the
formation of an association, but controlled for residual
effects of repeated SAC exposure and the known, strong
US properties of LiCl [28]. Animals in the EU groups
received SAC (CS) on the conditioning days, just as the
SAC + LiCl and SAC + BAC animals. On the following
day (the rest days) the EU animals were given an injec-
tion of either LiCl or BAC (2 or 3 mg/kg), 24 h after
the SAC presentation.
CTA extinction (EXT)
After the conditioning phase the animals were main-
tained on the 23-hr fluid deprivation schedule, but pre-
sented with SAC for 30 min daily. To prevent
dehydration the animals were given an additional 30
min water-drinking session, 15 min after SAC exposure
each day. The animals were maintained in this regimen
until they reached asymptotic extinction (90% reaccep-
tance of SAC as compared to baseline SAC drinking)
[21]. Note: The EU control groups were not included in
the extinction portion of the study since they were
already drinking high levels of SAC at the end of the
“conditioning” phase of the study and had no CTA to
be extinguished.
Statistical analysis
A repeated-measures ANOVA [Drug Treatment (LiCl,
2, 3 mg/kg BAC) × Day (Conditioning day 1, 3, 5)]
allowed us to analyze SAC consumption over the first
three conditioning days (first 3 CS exposures). Subse-
quent Tukey post hoc tests were used to determine if
there was a significant difference in SAC consumption
among drug treatment groups during conditioning. The
RM-ANOVA previously noted was repeated using ‘milli-
liters per 100 g of body weight’ (ml consumed/100 g)
instead of the direct milliliter consumption measure in
order to ensure there were no variances in reported
observations that could be attributable to body weight
differences. Furthermore, a one-way ANOVA was also
run to determine if body weights were significantly dif-
ferent within or between groups.
Consistent with the criterion set by Nolan and collea-
gues [21,29], the end point for asymptotic extinction in
our experiment was defined as SAC consumption
greater than or equal to 90% of the baseline [9,21]. A
one-way ANOVA and Tukey post hocs [Drug Treat-
ment: LiCl, 2, 3 mg/kg BAC] were used to determine if
there was a significant difference in the number of days
to reach asymptotic EXT across drug treatment groups.
As a first step in evaluating the degree to which the
rats in this study had extinguished their CTA, we
needed to estimate levels of baseline familiar saccharin
drinking. However, recording several days of baseline
saccharin pre-exposure in our animals would have
impeded future CTA training, due to latent inhibition
effects [30]. Moreover, we also wanted to record sac-
charin consumption over several days to avoid the bias
associated with the rat’s initial hesitation to consume
novel substances (neophobia) [31]. Therefore, baseline
saccharin consumption was determined by averaging
saccharin consumption on the third day of exposure
from a separate group (N = 10) of similarly-sized rats
maintained on the same fluid restriction schedule as the
rats in the studies reported here (see CTA Acquisition
section, above). This produced a mean saccharin con-
sumption (± SEM) = 17.57 ± 1.29 ml [21]. In order to
c o n f i r mt h a tt h i sm e t h o do fd etermining baseline sac-
charin consumption was consistent with other ways to
estimate familiar saccharin drinking, we also measured
the saccharin consumption of a group of rats (N =2 4 ;
also maintained on the same fluid restriction schedule
as the rats in the studies reported here) that were
exposed to saccharin and LiCl but did not have the US
and CS paired. Saccharin or LiCl were available/admi-
nistered on alternate days. The saccharin consumption
Wilson et al. BMC Research Notes 2011, 4:527
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Page 6 of 11of this group represented normal enhanced acceptance
of the sweet tasting liquid in the absence of conditioned
avoidance. The animals that had these explicitly
unpaired CS-US exposures over 3 saccharin-exposure
days drank amounts of the sweet liquid (Mean + SEM =
18.2 + 2.8 ml) not significantly different from those ani-
mals that only drank saccharin over the same time per-
iod (see data above). In a final pilot study, we employed
7 fluid-restricted rats on the same 23-hr fluid depriva-
tion schedule. Like the rats in the main study that went
through CTA acquisition, these pilot animals were
offered saccharin every-other day but, instead of receiv-
ing LiCl immediately after the saccharin, these rats
received an equal volume of physiological saline (i.p.).
On their third day of saccharin drinking, these rats
drank 17.10 ± 1.38 ml (Mean + SEM) of the sweet
liquid - an amount very similar to the baseline saccharin
consumption estimates from the other methods
described above. These data validated our method of
estimating baseline saccharin consumption as a compar-
ison point to determine 90% reacceptance of saccharin
as asymptotic extinction.
Results: experiment 2
All animals that received either a pairing of SAC + LiCl
or SAC + BAC acquired a CTA by the third condition-
ing trial. A one-way ANOVA showed no significant dif-
ferences between groups on the first SAC exposure day
(trial 1). However, the EU(LiCl), (EU)BAC2 mg/kg and
(EU)BAC3 mg/kg drank significantly more SAC on the
third trial compared to the SAC + LiCl and both SAC
+B A Cgroups, as illustrated in Figure 2 [F(5, 29) =
19.208, p < 0.001]. No other differences between these
groups were observed on this final acquisition trial.
As illustrated in Figure 3, the number of days required
for animals to reach asymptotic extinction of their CTA
was not significantly different between the SAC + LiCl
controls and the SAC + BAC 3 mg/kg rats. However,
the rats treated with BAC 2 mg/kg did extinguish signif-
icantly faster than both the SAC + LiCl and SAC +
BAC 3 mg/kg animals [F(2, 11) = 5.902, p ≤ 0.018]. EU
controls (receiving either LiCl or BAC explicitly
unpaired with SAC) were not included in Figure 3
because they were drinking “asymptotic levels” of SAC
on EXT day 1 and had no aversion to be extinguished.
There were no significant differences in average
weights among drug-treatment groups, as illustrated by
a one-way ANOVA comparison, nor were there signifi-
cant within-group differences. Furthermore, the statisti-
cal differences reported in fluid consumption remained
consistent when ‘ml fluid consumption per 100 g body
weight’ w a su s e da st h ed e p e n d e n tv a r i a b l ei nt h eR M -
ANOVA for conditioning, indicating that weight var-
iances did not impact reported results.
Discussion
Experiment 1 revealed that BAC dose-dependently (2
and 3 mg/kg, i.p.) reduced 0.3% vs. 0.6% SAC discrimi-
nation capabilities as well as total fluid consumption in
rats. Moreover, within-group comparisons indicated that
1 mg/kg BAC did not alter gustatory discrimination or
consummatory behaviors. At the higher doses of BAC,
we observed a decrease in liquid consumption (both
SAC and water) that is consistent with symptoms of
gastro-intestinal upset and/or neophobia [7,9]. While
neophobia would explain the decreased drinking of SAC
and water on the first BAC injection day, it would not
explain the subsequent decrease within BAC 2 mg/kg
and BAC 3 mg/kg groups on the second BAC injection
day, in experiment 1. In previous rat studies, we have
observed that neophobia to SAC disappears quickly, as
unconditioned animals increase their drinking from the
first to the second taste exposure and by the third taste
exposure animals are drinking asymptotic amounts of
the SAC [refer to [21]].
Both doses of BAC tested in experiment 2 (2 and 3 mg/
kg) did induce a CTA, as SAC consumption decreased
Figure 2 Experiment 2-CTA Acquisition.M e a nm lS A C .
Consumption (± SEM) on the Final Acquisition Trial. All animals that
received either SAC + LiCl or SAC + BAC pairings acquired a strong
taste aversion to SAC by the third CTA trial, as illustrated by the
significant difference in SAC drinking between animals given EU
training and those that had SAC paired with LiCl or BAC. All of the
EU groups that did not receive CS + US pairings did not acquire a
CTA, as indicated by high SAC drinking on trail 3, which was
significantly greater than their drinking on trial 1. The SAC + LiCl,
SAC + BAC 2 mg/kg and SAC + BAC 3 mg/kg groups were all
drinking near-zero amounts of SAC on trial 3, which was
significantly less than their SAC drinking on trial 1. Drinking on the
first conditioning trial was not significantly different between any
groups [Mean SAC consumption ± SEM on trial 1 = 4.35 ± 1.22 ml].
Note: A BAC 1 mg/kg group was not used in Experiment 2 because
this group did not indicate a disruption of SAC discrimination
capabilities in Experiment 1 nor did they demonstrate any possible
US effects of BAC exposure in Experiment 1. *Significant difference
between EU groups and the following CS + US groups: SAC + LiCl,
SAC + BAC 2 mg/kg, and SAC + BAC 3 mg/kg. p < 0.05
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Page 7 of 11significantly over 3 CS + US pairings in all animals
receiving SAC + BAC. This suppression was comparable
to that observed in rats that received SAC + LiCl. There-
fore, while compatible with some previous findings that
BAC does affect rats’ solid and liquid consummatory
behaviors [10,11,14], our experiment 2 additionally indi-
cated that induction of visceral malaise, by BAC (2 and 3
mg/kg) may lie behind certain behavior-modulating
effects of baclofen on liquid consumption. However, our
observations that a CTA formed as a result of pairing
SAC + BAC over 3 consecutive trials may be contrasted
with observations of Chester & Cunningham [13]. Che-
s t e ra n dC u n n i n g h a m[ 1 3 ]r e p o r t e dt h a t2m g / k g( i . p . )
BAC did not show US (malaise-causing) properties or
significantly affect SAC consumption, in control animals,
after one SAC + BAC pairing. Also, in their mouse study,
BAC (2 mg/kg, i.p) injections took place immediately
after SAC exposure. This may be compared to the timing
in both of our experiments (either 30 min prior to SAC
exposure, as in experiment 1, or paired immediately after
SAC exposure as the US, as in experiment 2). The num-
ber and timing of CS-US presentations and faster meta-
bolism of mice compared to rats may partially explain
this difference in the assessment of BAC’sU Sp r o p e r t i e s
in the context of a CTA paradigm [2,12]. Additionally, as
in our experiment 1, the decreased consumption after
one pairing of SAC followed by BAC 2 mg/kg may not
have reached statistical significance. However, the results
in our experiment 1 did indicate that consumption pat-
terns between BAC 2 mg/kg animals were different from
SAL control animals in that consumption of SAC did not
increase from the first to second SAC exposure.
An investigation into the differences in SAC consump-
tion patterns between the SAL and BAC 1 mg/kg
groups compared to the BAC 2 mg/kg and BAC 3 mg/
kg groups determined that BAC (2 and 3 mg/kg) can be
used as a reliable US in CTA experiments. Experiment 1
indicated that BAC at 1 mg/kg exhibited no US proper-
ties in rats. However, all rats that received BAC 2 or 3
mg/kg or LiCl paired with SAC over three trials exhib-
ited a strong CTA in Experiment 2. We found that BAC
(3 mg/kg) induced a conditioned taste aversion to SAC
that extinguished in a time-course similar to that of a
more conventional LiCl-induced SAC aversion [21].
However, the animals that received SAC + BAC(2 mg/
kg) pairings took less time to extinguish their CTA than
did rats receiving SAC + BAC(3 mg/kg) or SAC + LiCl
(81 mg/kg).T h e“floor effect” observed during acquisi-
tion may have obscured an indication of the varying
intensities of the CTA in each group, a difference which
was then only later revealed during EXT.
One may argue that the SAC + BAC(2 mg/kg) ani-
mals were not tasting the SAC on Day 3 or EXT Day 1
while the other groups may have been tasting more, on
average, so the SAC + BAC(2 mg/kg) group had only 2
effective pairings of SAC + BAC. But, average SAC con-
sumption in all groups did not differ significantly and all
were consuming near-zero SAC. It was observed that
most animals were at least tasting the SAC (consump-
tion ≤ 0.4 ml), so the argument that they may have been
getting the US in absence of the CS is not applicable in
this situation. Even so, as there were a few animals that
drank zero SAC on the final acquisition day, the time of
SAC presentation was controlled in all groups. Barnfield
and Clifton [32], showed that the duration of time the
CS is present is actually a more potent indicator and
control for taste aversion than is the volume of CS con-
sumed. This further supports a claim that the difference
in malaise-inducing properties of the US injections were
dose-dependent, rather than dependent on any variabil-
ity in final CS consumption. The dose-dependency of
BAC’s visceral effects, furthermore, would be a plausible
explanation for the observed differences in extinction
times; BAC at 2 mg/kg is a weaker US, while BAC at 3
mg/kg is comparable to the malaise-inducing properties
of LiCl (81 mg/kg, i.p.).
Due to the cascade of neurophysiological effects BAC
produces in the CNS [9,33] and its observed toxicity at
very high doses, it is not surprising that BAC may have
been perceived as noxious at doses used in our experi-
ments. Through direct action as a GABAB agonist, BAC
indirectly reduces levels of a variety of other neurotrans-
mitters (e.g., norepinephrine, dopamine, acetylcholine,
serotonin, glutamate, aspartate and GABA) [2,6,9,34].
Such neurotransmitter changes are capable of inducing
nausea, dizziness or confusion, among other effects, and
may very well be physiological mediators of CTA forma-
tion in BAC-treated animals (at doses of BAC above 1
Figure 3 Experiment 2-CS-Only Extinction. Mean Days (± SEM) to
Asymptotic EXT. The LiCl and BAC 3 mg/kg groups did not differ
significantly in the number of days required to reach asymptotic
EXT. However, the BAC 2 mg/kg group extinguished significantly
faster than the LiCl and BAC 3 mg/kg groups. * Significantly less
than both LiCl and BAC 3 mg/kg groups. p < 0.05
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Page 8 of 11mg/kg) [1,2,33]. Therefore, BAC may possess US prop-
erties through the modulation of these various neuro-
transmitter systems. Furthermore, Inui and colleagues
[35] showed data indicating that blockade of GABAA
receptors in the ventral pallidum is capable of altering
the taste palatability of SAC in a CTA paradigm. In our
second experiment, the EU(BAC 2 mg/kg) and EU
(BAC 3 mg/kg) rats did not consume significantly dif-
ferent amounts of SAC compared to the EU(LiCl) ani-
mals, indicating that there was likely not a significant
SAC palatability shift. However, it is important to note
such effects and realize that there could be a variety of
explanations and mechanisms driving the consumma-
tory behaviors in ours and other experiments, due to
t h ew i d er a n g i n ge f f e c t so ft h eG A B A e r g i cs y s t e m .I n
t h ep r e s e n ts t u d i e st h e r ea p p e a r st ob ead o s ed e p e n -
dency of BAC on consummatory behaviors: at 2 mg
BAC, and even more so at 3 mg/kg BAC, the US effects
of BAC are manifested in an observable manner via
measurable and statistically significant changes in the
animals’ consummatory behaviors and taste discrimina-
tion capacity. At 1 mg/kg (i.p.), the behavioral effects
associated with BAC’s toxicity or sensorium-altering
capabilities appear negligible for taste discrimination
and aversion investigations.
While it is clear that BAC (2 and 3 mg/kg) altered the
animals’ sensorium and was successfully used to induce
an observable CTA to SAC (indicated by a stark
decrease in SAC consumption following SAC + BAC
pairings that was only restored after repeated SAC-only
presentations) the mechanism by which BAC exerts
these US effects is still unclear. While CTAs are indeed
induced by malaise-inducing agents (such as LiCl) and
animals’ natural survival mechanisms that drive them to
avoid tastes associated with illness [22], this is not
always the case. While there is literature to support that
an aversion may not be formed in absence of gastro-
intestinal distress [refer to [36-38]], there is also new lit-
erature indicating that drugs inducing any change in an
animal’s sensorium, altering their psychological or physi-
cal state negatively or positively, can also induce a CTA
to a novel tastant. For example, Parker [34,39] showed
that animals can exhibit taste avoidance (which may be
interpretted as an aversion) when CS tastants are paired
with drugs possessing rewarding effects. Goudie and col-
leagues [40] also showed that conditioned nausea was
not always the necessary mediator of drug-induced con-
ditioned taste aversions. However, while avoidance to a
n o v e lt a s t a n tm a yb ei n d u c e db yb o t hp o s i t i v e l ya n d
negatively reinforcing drugs, a conditioned taste aversion
induced by malaise inducing (negative reinforcing) prop-
erties will be coupled with the Lay-On-Belly (LOB)
response [20] and conditioned disgust reactions such as
chin rubs and gapes [18]. Although we did not record
these conditioned disgust reactions, an argument that
BAC may have induced malaise is strengthened by the
observation that animals receiving SAC + BAC pairings
continued to avoid the SAC into the EXT phase of the
study even though they were not receiving any BAC
injection during this phase. Future studies, however,
should look at the conditioned disgust reactions in
attempt to elucidate whether or not the taste avoidance
and observed aversion in the present study was due to
malaise-inducing, emetic, or other negative reinforcing
properties of BAC or possibly due to another mechan-
ism related to BAC’s effects on other neurotransmitter
levels.
Overall, our data indicate that BAC given at 2 or 3
mg/kg (i.p.) impairs sensory abilities and decreases gus-
tatory discrimination in rats. But, these effects may be
augmented by dose-dependent US properties of BAC
that, when paired with the neutral gustatory stimulus,
SAC, induced a CTA in Experiment 2. Additionally, in
Experiment 2, rats acquired a strong CTA over 3 SAC +
BAC pairings and only over multiple days of CS-only
EXT training did SAC consumption return to asympto-
tic levels. These data carry implications for future
experiments that seek to use BAC in the context of con-
summatory paradigms. While studies available in the
most current literature avoid confounds of BAC admin-
istration (for examples refer to 12, 23, 34), our study
highlights the importance for investigators to control for
the dose-dependent US properties induced by systemic
BAC injections. The side-effects of BAC at doses equal
to or greater than 2 mg/kg (i.p.), in rats, can inadver-
tently alter results and affect conclusions drawn from
taste dependent paradigms. However, BAC may still suc-
cessfully be used in future CTA manipulations at doses
equal to and less than 1 mg/kg (i.p.), since our beha-
vioral measures did not differ between saline control
animals and those receiving the lowest dose of BAC in
Experiment 1. Development of novel GABAB agonists
void of taste-altering or malaise-inducing effects would
benefit future studies aimed at determining the role of
GABAergic neurons in taste aversion learning.
Conclusions
The GABAB agonist, BAC, decreased the ability of rats
to differentiate between 0.3% and 0.6% saccharin in a
two bottle preference test, when the drug was adminis-
tered intraperitoneally (i.p.) at doses of 2 mg/kg or 3
mg/kg. At 1 mg/kg (i.p.), BAC showed no signs of dis-
rupting gustatory discrimination, nor signs of inducing a
taste aversion to SAC. However, at 2 mg/kg and 3 mg/
kg, BAC showed unconditioned stimulus effects that
were sufficient to create a CTA to SAC. Futhermore, 3
mg/kg BAC induced a CTA to SAC that was compar-
a b l et ot h em o r ec o n v e n t i o n a lS A C+L i C l( 8 1m g / k g )
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Page 9 of 11paradigm. Future experiments should include observa-
tions of orofacial responses indicative of conditioned
disgust (e.g., gapes, chin rubs, paw treads) and avoid-
ance. Subsequent studies may also include more exten-
sive observations of visceral malaise such as the Lay-
On-Belly measure in order to fully conclude that the
conditioned taste aversion and avoidance induced by
BAC in the present study was attributable to gastroin-
testinal distress associated with the BAC injection
instead of other central aversive effects that may have
also led in part to the observed hypodipsia in lieu of
visceral malaise.
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